Commercial Models: Change Is Underfoot In Europe, Too
This article was originally published in The Pink Sheet Daily
As European payers get more demanding, pharmaceutical commercial strategies are evolving even faster than in the U.S.
You may also be interested in...
Thanks to a new deal with GlaxoSmithKline for the marketing of its cherished bone drug denosumab outside the U.S. in post-menopausal osteoporosis, Amgen gets a much needed, solid launch pad for its first major venture into primary care
D-mab is the new EPO. At least, that's what Amgen is hoping as it awaits FDA approval for its next growth engine, denosumab (D-mab). Assuming the drug gets to market--and Amgen is very confident it will--the drug's success will depend largely on pricing.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.